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ABSTRACT
MicroRNAs (miRNAs) are known to function as oncomiRs or tumor suppressors 
and are important noncoding RNA regulators of oncogenesis. The miR-200c/141 locus 
on chromosome 12 encodes miR-200c and miR-141, two members of the miR-200 
family, which have been shown to function as tumor suppressive miRNAs by targeting 
multiple oncogenic factors such as polycomb group protein BMI1. Here, we show 
that BMI1 reciprocally functions as a transcriptional repressor of the miR-200c/141 
cluster and that BMI1 inhibitors upregulate expression of miR-200c and miR-141. 
Our data suggest that BMI1 binds to the miR-200c/141 promoter and regulates it 
through transcription factor binding motifs E-box 2 and Z-box 1 to repress expression 
of miR-200c/141 cluster. We also show that PTC-209, a small molecule inhibitor of 
BMI1 gene expression induces cellular senescence and transcriptionally upregulates 
expression of miR-200c/141 cluster in breast cancer cells. Furthermore, inhibition 
of expression of miR-200c or miR-141 overcomes tumor suppressive effects of PTC-
209 including induction of cellular senescence and downregulation of breast cancer 
stem cell phenotype. Therefore, our studies suggest a reciprocal regulation between 
BMI1 and miR-200c/141 cluster, and that BMI1 inhibitory drugs can further amplify 
their inhibitory effects on BMI1 via multiple mechanisms including posttranscriptional 
regulation by upregulating BMI1 targeting miRNAs.
INTRODUCTION
MicroRNAs (miRNAs) are evolutionarily conserved 
small non-coding RNA molecules of 19-24 nucleotides in 
length, which control expression of target genes via base 
pairing to seed sequences that are found in 3’ untranslated 
region of a particular target gene [1, 2]. MiRNAs have 
recently emerged as major regulators of cancer and 
other human diseases [3, 4]. During cancer progression, 
miRNAs can function either as oncogenes (oncomiRs) 
or tumor suppressors [5, 6]. Accordingly, several 
miRNAs are known to be significantly downregulated 
or overexpressed in various cancer cells including breast 
cancer cells [7]. For example, miR-21, miR-155, miR-10b 
and miR-29 are overexpressed, whereas let-7, miR-200 
family, miR-125a/b, miR-206, miR-17, miR-34a and miR-
31 are downregulated in breast cancer cells [7, 8].
The miR-200 family members, which include miR-
200c, miR-141, miR-200a/b and miR-429, exert tumor 
suppressor function by inhibiting epithelial to mesenchymal 
transition (EMT), cell motility, anoikis resistance and cancer 
stem cell phenotype [9–11]. The PcG proteins BMI1 and 
EZH2 are two important constituents of the polycomb 
repressive complex PRC1 and PRC2 respectively [12, 13]. 
The constituents of PRC1 and PRC2 including BMI1 and 
EZH2, are often overexpressed in breast, prostate and colon 
cancer cells [14–16], and regulate oncogenic phenotypes 
[17–20]. In particular, PcG protein BMI1 promotes cancer 
stem cell (CSC) phenotype and therapy resistance in cancer 
cells [14, 21]. It also regulates cellular senescence via 
repression of tumor suppressor p16INK4a [22, 23]. Because 
of its role in promoting oncogenic properties including CSC 
phenotype, inhibitors of BMI1 are of clinical importance. 
These inhibitors include miRNAs (miR-200c, miR-141 
and miR-31), WNT inhibitors and certain pharmacological 
inhibitors [24–28], and a recently described cell permeable 
small molecule inhibitor PTC-209 [29]. PTC-209 represents 
a new class of inhibitors of gene expression that was 
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identified using Gene Expression Modulation by Small 
Molecules (GEMS) technology designed to screen out 
small molecules that can inhibit BMI1 gene expression via 
interaction with its 5’ and 3’ untranslated regions (UTR) [29].
The miR-31 was recently shown to be negatively 
regulated by the PcG protein EZH2 in adult T cell leukemia 
(ATL) cells [30]. In addition, we recently reported that 
PcG protein BMI1 is a negative regulator of miR-31 [26]. 
Recently, we showed that expression of the PcG proteins is 
inhibited by histone deacetylase inhibitors (HDACi) [24], 
and that HDACi may work through upregulation of miR-
200c/141 cluster [27]. We also showed that inhibitors of 
polo-like kinase 1 (PLK1) can upregulate miR-200c/141 
cluster, which indirectly results in downregulation of BMI1 
and cancer stem cell phenotype [28]. In this study, we 
show that similar to miR-31 regulation by PcG proteins, 
BMI1 negatively regulates expression of miR-200c and 
miR-141, which targets BMI1 mRNA for degradation [27]. 
We further studied regulation of miR-200c/141 cluster by 
PTC-209, a clinically relevant small molecule inhibitor of 
BMI1 and CSC phenotype [29].
RESULTS
BMI1 transcriptionally regulates expression of 
miR-200c/141 cluster
The EMT transcription factor ZEB1 negatively 
regulates miR-200c/141 cluster via an autoregulatory 
loop [31]. We recently showed that both miR-200c and 
miR-141 can target BMI1 [28]. We have also reported 
that an indirect inhibition of BMI1 by PLK1 inhibitor 
can lead to upregulation of miR-200c/141 cluster [28], 
suggesting that BMI1 may directly regulate it via an 
autoregulatory loop similar to the reciprocal regulation of 
ZEB1 and miR-200c/141 cluster. To test this hypothesis, 
we transiently overexpressed BMI1 or downregulated it 
using a transient transfection of a BMI1 shRNA vector in 
293T (a derivative of HEK293) cells, and determined the 
expression of both miR-200c and miR-141 by qRT-PCR. 
The results showed that the transient BMI1 overexpression 
led to a dose-dependent decrease in expression of miR-
200c and miR-141, and a dose-dependent increase in 
expression of both of these miRNAs by transient BMI1 
knockdown in 293T cells (Figure 1A, 1B).
To further confirm these results, and determine the 
mechanism of downregulation of miR-200c/141 cluster, 
we performed promoter-reporter assays using transient 
transfection of pGL-miR-200c/141 promoter construct 
with HA-BMI1 (for BMI1 overexpression) and pRS-
BMI1shRNA (for BMI1 knockdown) plasmids in 293T 
cells. Our results indicated a dose-dependent decrease 
in the reporter activity with overexpression of BMI1 
and a dose-dependent increase in its activity upon BMI1 
knockdown (Figure 2A), thereby confirming transcriptional 
downregulation of miR-200c/141 cluster by the PcG protein 
BMI1. PcG proteins including BMI1 are known to directly 
bind their target loci [32]. Hence, to determine whether 
Figure 1: BMI1 regulates expression of miR-141 and miR-200c. A. 293T cells were transiently transfected with HA-BMI1 (left 
panel) or pRS-shBMI1 (right panel). After 48 hrs, the total cell lysates were prepared from transfected cells and the expression of BMI1, 
p16 (a BMI1 target) and β-actin was detected by Western blot analysis using specific antibody against each protein. B. Downregulation 
of miR-141 and miR-200c by BMI1 overexpression (left panel), and upregulation of miR-141 and miR-200c by BMI1 knockdown (right 
panel) were confirmed by qRT-PCR in the above set of cells as described in the Methods. Error bars represent ±S.D, * p <0.05.
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BMI1 directly binds to the miR-200c/141 promoter region, 
we performed a chromatin immunoprecipitation linked 
PCR (ChIP) analysis using chromatin-IP with the BMI1 
monoclonal antibody (mAb) and qPCR amplification using 
4 different primer sets that cover the promoter region of 
the miR-200c/141 locus contained in the pGL4.18 vector 
used in reporter assays. The primer sets were designed to 
amplify 4 known cis-regulatory transcription factor (TF) 
binding sites (E-box 2, E-box 3, Z-box 1 and Z-box 2) in 
the miR-200c/141 promoter [31, 33]. These TF binding sites 
are involved in the regulation of miR-200c/141 promoter 
by an epithelial-mesenchymal transition (EMT) inducing 
transcription factor ZEB1 [31]. The results of ChIP analysis 
indicated significant binding of BMI1 to only region 2, 
which contained E-box 2 and Z-box 1 TF binding sites 
(Figure 2B). Although it is not clear whether BMI1 can 
bind to its target genes independent of PRC1, it was recently 
reported that it binds to an 89 bp region containing BMI1 
response region (BRE) in the p16 promoter via canonical 
PRC1-independent binding [34]. The exact mechanism of 
BMI1 binding to region 2, which has very weak homology 
to p16 BRE (not shown), remains to be explored. It could 
include binding of BMI1 via its H-T-H-T (helix-turn-helix-
turn) or RF (Ring finger) motifs [35], independent of PRC1. 
Collectively, our results suggested that BMI1 regulates miR-
200c/141 promoter via E-box 2 and Z- box 1 cis-regulatory 
TF sites present in the region 2 (Figure 2B).
BMI1 regulates expression of miR-200c/141 
via E-box 2 and Z-box 1 of the miR-200c/141 
promoter
The upstream region of hsa-miR-200c/141 
promoter and spacer region between miR-200c and miR-
141 genes contain four E-boxes (E-box 1, 2, 3 and 4, 
GAGGTG) and two Z-boxes (Z-box 1 and 2, CAGGTA) 
[31]. Since, our cloned promoter region contains four 
of these putative TF binding motifs, E-box 2 and 3, 
and Z-box 1 and 2 (Figure 2A), we reasoned that BMI1 
possibly regulates miR-200c/141 cluster by binding to 
one of these motifs. Furthermore, E-Box 2 and Z-Box 1 
are located in the sequence region which was amplified 
with the primer set 2 in ChIP analysis. Therefore, 
we hypothesized that BMI1 regulates miR-200c/141 
expression via these two binding motifs (E-box 2 and 
Z-box 1). To test this hypothesis, we generated 4 mutants; 
mutant 1 (M1) in which E-box 2 was mutated, mutant 
2 (M2) in which Z-box 1 was mutated, mutant 3 (M3) 
in which both E-box 2 and Z-box 1 were mutated, and 
mutant 4 (M4) in which E-box 3 was mutated (Figure 
3A). Since BMI1 does not seem to bind to the region 3 of 
miR-200c/141 promoter, which was amplified by primer 
set 3 in ChIP analysis, we expected that BMI1 would not 
repress it through E-box 3 and therefore used M4 as a 
negative control.
Next, we performed promoter-reporter assays with 
the wild type (WT) and mutants (M1-M4) promoter-
reporter constructs. Our results showed significantly 
increased levels of promoter activity in M1, M2 and 
M3 as compared to the wild-type promoter (Figure 3B). 
Especially, much higher activity was noted in M3, which 
has both M1 and M2 mutations (Figure 3B). M4 exhibited 
much lower activity similar to wild type suggesting that 
the inhibitory sequences to which BMI1 may bind are 
intact in M4 and wild type but not in M1, M2 and M3 
mutants. These results imply that both E-box 2 and Z-box 
1 act as regulatory motifs for transcriptional repression 
of the miR-200c/141 cluster, and E-box 3, which was 
Figure 2: BMI1 transcriptionally regulates miR-200c/141 promoter. A. 293T cells were transiently transfected with miR-
200c/141 promoter-reporter (pGL4.8-PmiR-200c/141) and pTK-Luc plasmids with HA-BMI1 or pRS-shBMI1 plasmids, and normalized 
luciferase activity was determined after 48 hrs and plotted. B. Binding of BMI1 to miR-200c/141 promoter was studied by ChIP assay. Four 
different sets of primers covering 683 bp of miR-200c/141 promoter region were designed to amplify BMI1 immunoprecipitated chromatin 
and the qPCR was performed as described in the Experimental Methods. The approximate position of E-box 2, Z-Box 1, E-Box 3, and 
Z-box 2 are indicated in the promoter region. Error bars represent ±S.D, * p <0.05.
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mutated in M4 is not a regulatory motif for BMI1-
mediated repression of the miR-200c/141 locus.
Next, to determine whether regulation of the miR-
200c/141 promoter by BMI1 indeed requires E-box 2 
and Z-box 1, we tested promoter activity of the WT, M1, 
M2, M3 and M4 reporter constructs with overexpression 
or knockdown of BMI1. For BMI1 overexpression, we 
generated 293T cells stably overexpressing BMI1 using 
pBabe-BMI1 retrovirus (Figure 3C). The knockdown 
studies were performed using 293T cells transiently 
transfected with mock or 3 μg of pRS-BMI1shRNA 
vector (Figure 3D). The relative promoter activity of 
WT and all mutants (M1-M4) in 293T-B0 (control) and 
293T-BMI1 (BMI1 overexpression) cells was analyzed by 
the reporter assay. Our results indicated that the promoter 
activity of WT and M4 mutant constructs is significantly 
repressed in BMI1 overexpressing cells (Figure 3C), but 
M1, M2 and M3 did not respond to BMI1 overexpression 
(Figure 3C). These results suggest that BMI1 regulates 
miR-200c/141 promoter via through both E-box 2 and 
Z-box 1 motifs. In agreement with these results, the WT 
and M4 promoter-reporter constructs exhibited higher 
promoter activity in BMI1 knockdown cells (Figure 
3D). On the other hand, the promoter activity of M1, 
M2 and M3 was not affected by the BMI1 knockdown 
(Figure 3D). These results together with the ChIP analysis 
indicate that BMI1 regulates miR-200c/141 promoter via 
E-box 2 and Z-box 1.
Figure 3: E-box 2 and Z-box 1 are regulatory motifs for miR-200c/141 regulation by BMI1. A. Schematic representation 
of generation of M1, M2, M3 and M4 mutants by site directed mutagenesis. In M1, CACCTG of the E-box 2 was changed to CACCGG, 
in M2, CAGGTA of the Z-box 1 was changed to TAGGCA, M1 and M2 primers were combined to generate M3 (double mutant). In 
M4, CAGGTG of the E-box 3 was changed to GAGGTT. B. The relative promoter activity of wild type (WT), M1, M2, M3 and M4 
miR-200c/141 promoter-reporter constructs was determined in 293T cells by transient transfection assay as described above in Figure 
2. C. The relative promoter activity of wild-type and mutant miR-200c/141 promoter-reporter constructs was determined in stable BMI1 
overexpressing cells by transient transfection of reporters. B0 control and BMI1 overexpressing 293T stable cell lines were analyzed for 
the expression of BMI1, p16 and β-actin by Western blot analysis, and relative promoter activity of WT and M1, M2, M3 and M4 reporter 
constructs in B0 control and BMI1 cells was determined as described in the Figure 2. D. The relative promoter activity of wild-type 
and mutant miR-200c/141 promoter-reporter constructs was determined in BMI1 knockdown cells by transient transfection. Mock and 
BMI1 knockdown cells were generated by transient transfection of the 3 μg of pRS-shBMI1 plasmid. After transfection with the reporter 
constructs, cells were analyzed for the expression of BMI1, p16 and β-actin by Western blot analysis, and relative promoter activity of WT 
and M1, M2, M3 and M4 reporter constructs was determined as described in the Figure 2.
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BMI1 inhibitor PTC-209 upregulates expression 
of the miR-200c/141 cluster
Recently, PTC-209 a small molecule inhibitor 
of BMI1 selected by GMS technology was reported to 
downregulate BMI1 and colon cancer stem cell (CSC) 
phenotype in a colorectal cancer model [29]. The PTC-
209 does not inhibit BMI1 function by interacting with 
the protein but rather downregulates BMI1 transcripts 
via posttranscriptional mechanism, which is likely to 
be specific to BMI1. We hypothesized that PTC-209 
downregulation of BMI1 may upregulate miR-200c/141 
cluster, which could further downregulate BMI1 and 
oncogenic phenotypes of the cancer cells. To test this 
hypothesis, we first determined whether PTC-209 treatment 
indeed results in upregulation of miR-200c and miR-
141 by qRT-PCR analysis and promoter-reporter assays. 
293T cells were treated with different concentrations 
of PTC-209 and the expression of BMI1, EZH2, total 
H2A, H2AK119Ub, total H3, AcH3 and H3K27me3 
was determined by the Western blot analysis. In parallel, 
expression of miR-200c and miR-141 was determined by 
qRT-PCR analysis. Consistent with the published data in 
colorectal cells, PTC-209 treatment resulted in specific 
downregulation of BMI1 and H2AK119Ub (Figure 4A). 
The expression of EZH2, H3K27me3 and AcH3 was not 
affected by PTC-209 (Figure 4A). Importantly, PTC-209 
treatment resulted in upregulation of both miR-200c and 
miR-141 (Figure 4B). The results of qRT-PCR were further 
confirmed by promoter-reporter assays, which showed that 
Figure 4: PTC-209 inhibits BMI1 expression, and upregulates miR-200c and miR-141. A. 293T cells were mock treated 
(with DMSO) or treated with the indicated dose of PTC-209 for 48 hours and the expression of BMI1, EZH2, p16, β-actin, H2AK119Ub, 
total H2A, H3K27me3, AcH3 and total H3 was determined by Western blot analysis. B. Expression of miR-200c and miR-141 in mock 
and PTC-209 treated 293T cells was determined by qRT-PCR analysis. C. Luciferase activity of pGL4.8-PmiR-200c/141 was determined 
in mock or PTC-209 treated cells as described in the Figure 2. D. Western blot analysis of BMI1, H2AK119Ub, total H2A and β-actin in 
mock or PTC-209 treated MDA-MB-231 (left) and MCF7 (right) cells. In parallel, the mock and PTC-209-treated cells were analyzed for 
the expression of miR-141 and miR-200c by qRT-PCR analysis (bottom panels). Error bars represent ±S.D, * p <0.05.
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the PTC-209 upregulated miR-200c/141 promoter activity 
in a dose-dependent manner (Figure 4C). Similar results 
were obtained with MCF7 and MDA-MB-231 cells upon 
treatment with PTC-209 (Figure 4D).
Next, to determine the mechanism of PTC-209 
mediated upregulation of the miR-200c/141 promoter 
activity and whether PTC-209 regulation involves E-box 2 
and Z-box 1, we performed promoter-reporter assays using 
transient transfection of wild type and different mutant 
(M1, M2, M3 and M4) reporters into the B0 control and 
BMI1 overexpressing 293T cells. The results indicated 
that PTC-209 had no effect on constitutively expressed 
BMI1 (Figure 5A). As expected, it only downregulated the 
endogenous BMI1 (Figure 5A). Accordingly, only wild 
type and M4 mutant reporters were upregulated in a dose-
dependent manner by PTC-209 in B0 cells, presumably 
due to downregulation of endogenous BMI1 by PTC-209 
(Figure 5B). In BMI1 overexpressing cells, the wild type 
and M4 reporter activity was significantly lower compared 
to the B0 control cells, and remained lower even after 
PTC-209 treatment presumably because the exogenously 
overexpressed BMI1 is not affected by PTC-209 (Figure 
5B). The M1, M2 and M3 were not affected in either B0 
or BMI1 overexpressing cells (Figure 5B). These mutant 
reporters exhibited higher activity than wild type and M4 
reporters because the potential repressor sites are mutated 
in M1, M2 and M3 (Figure 5B). Based on these results, 
we propose that PTC-209 upregulates miR-200c/141 via 
downregulation of the endogenous BMI1 and that PTC-
209 does not directly upregulate miR-200c/141 locus. 
Collectively, our data suggest that BMI1 inhibition by 
PTC-209 or its knockdown upregulates expression of 
miR-200c and miR-141, which further targets BMI1, 
thereby maintaining expression of both BMI1 and miR-
200c/141 cluster via an autoregulatory loop.
PTC-209 induces premature cellular senescence
PTC-209 strongly inhibits growth of colon cancer 
cells and CSC phenotype, and BMI1 downregulation using 
siRNA approach or its inhibition by histone deacetylase 
inhibitors (HDACi) and PLK1 inhibitors is known to 
induce premature senescence in normal and breast cancer 
cells [27, 28, 36]. Hence, first we determined whether 
PTC-209 can induce premature cellular senescence in 
MRC5 fibroblasts. Cells were either mock treated or 
treated with 0.5 μM and 1 μM of PTC-209 for 48 hrs 
and stained for senescence associated-beta-galactosidase 
(SA-β-gal) and EdU (5’ ethynyl -2’-deoxyuridine, a 
thymidine analog). The stained cells were counted and 
plotted. We also examined the expression of senescence-
associated proteins such as p21, p53, pRB and p16. 
The results showed that the PTC-209 strongly induced 
expression of p53, p21 and p16, and increased expression 
of hypo-phosphorylated pRB in MRC5 cells (Figure 
6A). Furthermore, PTC-209 strongly induced premature 
senescence in these cells as indicated by increase in SA-
β-gal positive cells and corresponding decrease in EdU 
positive cells (Figure 6B). PTC-209 also strongly induced 
premature senescence in MDA-MB-231 and MCF7 breast 
cancer cells (Figure 6B middle and right panels). Thus, 
by inhibiting BMI1, PTC-209 strongly induces premature 
cellular senescence in normal fibroblasts and breast cancer 
cells suggesting that PTC-209 also inhibits cancer cell 
growth via induction of premature senescence, which is a 
known tumor-suppressive mechanism.
Inhibition of miR-200c and miR-141 overcomes 
PTC-209 inhibitory effects on oncogenic 
phenotypes
Next, to determine the functional significance of the 
miR-200c/141-BMI1 autoregulatory loop, we examined 
whether PTC-209 inhibits oncogenic activity of BMI1 
via upregulation of miR-200c/141 cluster. First, we 
determined whether knockdown of miR-200c and miR-
141 can overcome the induction of premature senescence 
by PTC-209 in MDA-MB-231 and MCF7 cells. We 
generated MDA-MB-231 and MCF7 cells expressing a 
control vector and inhibitors of miR-200c and miR-141 
Figure 5: PTC-209 upregulates miR-200c/miR-141 cluster via E-box 2 and Z-box 1 cis-regulatory sites. A. Control B0 
and BMI1 overexpressing 293T cells were mock- or PTC-209- treated for 48 hrs. The total cell lysates were analyzed for the expression 
of BMI1 and its target p16 by Western blot analysis as described in Figure 1. B. Control B0 and BMI1 overexpressing 293T cells were 
transiently transfected with wild type (WT), M1, M2, M3 and M4 luciferase reporters constructs. The cells were mock- or PTC-209- treated 
for 48 hrs., and the luciferase activity of the reporters was determined as described in Figure 2.
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designated as control IH, miR-200c IH and miR-141 IH 
breast cancer cells respectively. Next, cells were either 
mock treated or treated with 1.0 μm PTC-209 for 48 hrs, 
and then examined for the expression of miR-200c and 
miR-141. The results indicated that PTC-209 treatment 
led to induction of miR-200c and miR-141 in control IH 
but not in miR-200c IH and miR-141 IH breast cancer 
cells (Figure 7A). We also analyzed expression of BMI1, 
H2AUb, H2A and p21 using Western blot analysis. Our 
data indicated that compared to control IH cells, PTC-209 
did not significantly downregulate BMI1 and H2AUb in 
miR-200c IH and miR-141 IH cells (Figure 7B). Because 
these cells are p16 negative, we only determined the 
expression of p21 as a senescence effector in this context. 
The results showed that the PTC-209 strongly induced p21 
in control IH cells and that inhibition of either miR-200c 
or miR-141 could suppress p21 induction by PTC-209 
(Figure 7B). Next, mock- and PTC-209- treated cells were 
plated for SA-β-gal and EdU co-staining. The percent 
positives for each marker were quantified and plotted. 
The results indicated that the PTC-209 treatment led to 
the induction of premature senescence in control IH cells 
but not in cells expressing inhibitors of either miR-200c or 
miR-141 (Figure 7C, 7D). Similar results were obtained in 
MCF7 cells (not shown).
We further studied whether PTC-209 inhibits soft 
agar colony formation, migration and invasion in MDA-
MB-231 cells, and whether miR-141 and miR-200c 
inhibitors can overcome the inhibitory effect of PTC-209 
on these oncogenic phenotypes (Figure 8). The results 
of the soft-agar colony formation suggest that PTC-209 
significantly inhibited soft agar colony formation in control 
IH but not in miR-200c IH and miR-141 IH cells (Figure 
8A). Similarly, results of the migration and invasion assays 
showed that inhibition of either miR-200c or miR-141 can 
overcome PTC-209 mediated inhibition of migration and 
invasion in MDA-MB-231 cells (Figure 8B, 8C).
The PTC-209 exhibits remarkable inhibitory activity 
towards colon CSCs [29, 37]. Hence, we examined 
whether PTC-209 similarly inhibits breast CSC phenotype 
using mammosphere and Aldefluor assays. The control IH, 
miR-200c IH and miR-141 IH breast cancer cells were 
plated for mammosphere formation, and treated with PTC-
209. After 5 days the numbers and sizes of mammospheres 
were counted, photographed and plotted (Figure 9A, 9B). 
The results of mammosphere formation assay indicated 
that PTC-209 strongly inhibits mammosphere formation 
in control MDA-MB-231 and MCF7 cells, and that 
downregulation of either miR-141 or miR-200c using 
respective inhibitors is sufficient to overcome inhibition 
of mammosphere formation by PTC-209 (Figure 9A, 9B).
Next, we carried out the Aldefluor assay to analyze 
aldehyde dehydrogenase isoform 1 (ALDH1) activity, 
which is a known marker of the breast CSCs [38]. 
The control IH, miR-200c IH and miR-141 IH breast 
cancer cells were plated, treated with 1 μM PTC-209 
for 48 hrs and ALDH1 activity was determined using 
the ALDEFLUOR assay kit (Stem Cell Technologies, 
Vancouver, BC, Canada). The results indicated that PTC-
209 treatment led to 84% decrease of ALDH1 activity 
in control MDA-MB-231 cells, while miR-141 IH and 
miR-200c IH cells exhibited 30% and 28% decrease 
respectively with PTC-209 treatment (Figure 10A). The 
miR-141 IH and miR-200c IH cells exhibit higher ALDH1 
Figure 6: PTC-209 induces premature cellular senescence in human cells. A. Western blot analysis of BMI1, H2AK119Ub, 
total H2A and β-actin and molecular markers of senescence (p53, p21, pRB and p16), in MRC5 cells. The cells were mock treated or treated 
for 48 hrs with PTC-209. B. MRC5, MDA-MB-231 and MCF7 cells (as indicated) were treated with PTC-209 for 48 hrs and co-stained 
with SA-β-gal and EdU to determine the induction of premature senescence by PTC-209. The number of positive cells were counted in 4 
random fields and % positive cells for each marker plotted as shown. Error bars represent ±S.D, * p <0.05.
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activity compared to control IH, confirming the negative 
regulatory role of miR-141 and miR-200c in breast CSC 
phenotype. Similar results were obtained with MCF7 
cells (not shown). Thus, our data indicate that inhibition 
of miR-141 and miR-200c partially reversed the decrease 
in ALDH1 activity caused by the PTC-209 treatment.
We also analyzed expression of CD44, a known 
marker of breast CSCs by FACS analysis of PTC-209 
treated control and miR-200c or miR-141 inhibitor 
expressing cells. The data indicated that PTC-209 treatment 
for 48 hrs led to a 40% decrease in CD44 expression 
in control cells, while in miR-141 IH and miR-200c IH 
cells the decrease in CD44 expression was only 4% and 
7% respectively (Figure 10B). These data indicate that 
inhibition of either miR-200c or miR-141 can overcome 
the decrease in fraction of CD44 expressing cells by PTC-
209 treatment. Collectively, our data indicate that PTC-
209 induced inhibition of CSC phenotype is mediated by 
upregulation of miR-200 family members miR-200c and 
miR-141, and that the inhibition of either of these family 
members can overcome the inhibitory effect on oncogenic 
phenotypes by PTC-209 in breast cancer cells.
DISCUSSION
PcG protein BMI1 is an important regulator of 
proliferation and cell senescence [22, 23]. It also regulates 
oncogenic phenotypes such as migration, invasion and 
metastasis of cancer cells [17, 18, 22, 39, 40]. More 
importantly, BMI1 promotes CSC properties and therapy 
resistance in breast, prostate, lung and colorectal cancers 
[20, 41]. Therefore, therapeutic targeting of BMI1 could 
help in the treatment of breast, prostate, colorectal 
and possibly other cancers, and overcome the disease 
Figure 7: Inhibitors of miR-141 and miR-200c overcome induction of premature senescence by PTC-209 in breast 
cancer cells. A. qRT-PCR analysis of miR-141 and miR-200c in control, miR-141 inhibitor and miR-200c inhibitor expressing cells. 
B. Western blot analysis of BMI1, H2AK119Ub, total H2A, p21 and β-actin in control, and miR-141 and miR-200c inhibitors expressing 
MDA-MB-231 cells treated with DMSO (mock) or PTC-209 (1.0 μM) for 48 hrs. C. SA-β-gal/EdU co-staining of control, and miR-141 and 
miR-200c inhibitors expressing MDA-MB-231 cells either mock or PTC-209 treated as described in the Methods. D. The percent positive 
SA-β-gal and EdU stained cells were counted and plotted. Error bars represent ±S.D, * p <0.05, NS- not significant.
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recurrence. BMI1, EZH2 and other PcG proteins can be 
targeted by pharmacological inhibitors of HDACs [24, 
42], which are known for tumor suppressive properties. 
More recently, PTC-209, a small molecule inhibitor of 
BMI1 was shown to target self-renewal of colon CSCs 
and inhibit colorectal cancer [29, 43]. While targeting of 
self-renewal of colon CSCs by PTC-209 is likely to be 
due to the downregulation of BMI1, it is not clear how 
mechanistically PTC-209 downregulates BMI1. Since, the 
reporter used in the identification and characterization of 
PTC-209 contained 5’ and 3’ untranslated region (UTR) of 
the BMI1 gene (29), it is possible that PTC-209 regulates 
BMI1 via miRNAs that target 3’UTR of the BMI1 gene. 
It is also possible that PTC-209 directly upregulates 
miRNAs that inhibit CSC phenotype. Hence, here we 
focused on miR-200c and miR-141, which are known 
to posttranscriptionally target BMI1 and its oncogenic 
activity including regulation of CSC phenotype [27, 28, 
41]. Because PTC-209 exhibits strong tumor suppressive 
activity, it is likely that it also regulates cellular senescence, 
which is a natural tumor suppressor mechanism [44]. 
Indeed, our data demonstrate that PTC-209 strongly induces 
premature senescence not only in normal human diploid 
fibroblasts but also in breast cancer cells. Previously, we 
have shown that both miR-141 and miR-200c are important 
regulators of cell senescence (27,28). Although it is possible 
Figure 8: PTC-209 inhibits oncogenic phenotypes in MDA-MB-231cells and inhibitors of miR-200c and 141 overcome 
PTC-209 inhibitory effects. A. Soft-agar colony formation assay, B. Migration and C. Invasion assay of control, and miR-141 and 
miR-200c inhibitors expressing MDA-MB-231 cells treated with DMSO (mock) or PTC-209 (1.0 μM) for 7 days (soft agar), or 48 hrs 
(migration and invasion assays). The number of colonies (soft agar), migrated and cells that invaded through Matrigel were quantified and 
plotted as described in the Methods. Error bars represent ±S.D, * p <0.05, NS- not significant.
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that these miRNAs can induce senescence via regulation of 
other molecular targets, BMI1 is an established regulator 
of senescence, hence, it is likely that PTC-209 induces 
senescence by perturbing the miR-200c/141-BMI1 
autoregulatory loop. Indeed, our results show that by 
inhibiting miR-200c or miR-141, the senescence inducing 
activity and other tumor suppressive activities of PTC-209 
can be abrogated in breast cancer cells.
ZEB1 and miR-200c/141 regulate each other via 
a negative feedback loop or reciprocal repression [31]. 
We have recently shown that a similar autoregulatory 
loop regulates expression of the PcG proteins and miR-
31, another tumor suppressive miRNA [26]. Here, we 
propose a similar model to regulate expression of miR-
200c/141 and BMI1, and physiological function of 
BMI1 (Figure 11). Although, here we mainly focused 
on the physiological function of BMI1 in the context 
of the CSC regulation, BMI1 is a known regulator of 
normal and adult stem cells [45]. It’s deficiency causes 
depletion of neural, hematopoietic and other adult 
organ-specific stem cells in the mouse model, and 
BMI1 knockout mice exhibit segmental features of the 
accelerated ageing and other pathologies such as type II 
diabetes [23, 43, 46–48]. Hence, it is likely that miR-
200c/141-BMI1 autoregulatory loop is highly relevant to 
the ageing process (Figure 11). In summary, our studies 
suggest that BMI1 autoregulates its expression via 
repression of miR-200c/141 locus, and BMI1 inhibitory 
reagents such as PTC-209 and possibly HDACi inhibit 
BMI1 expression via upregulation of miR-200c/141 
cluster, which can further downregulate BMI1 by 
posttranscriptional mechanism. BMI1 is an important 
physiological regulator [43], as its deregulation is 
associated with cancer, and adult stem cell depletion and 
accelerated ageing. We speculate that this autoregulatory 
loop maintains a basal endogenous level expression 
of BMI1 and miR-200c/141 necessary for the proper 
physiology of an organism, and that its deregulation 
can result in pathological conditions such as cancer and 
ageing.
Figure 9: PTC-209 inhibits mammosphere formation, and inhibition of miR-141 and miR-200c overcomes PTC-209 
inhibitory activity on mammosphere formation in breast cancer cells. The mammosphere formation assay using control, 
and miR-141 and miR-200c inhibitors expressing MDA-MB-231 or MCF7 cells treated with DMSO (mock) or PTC-209 (1.0 μM) (as 
indicated) was performed as described in the Methods. The number of mammospheres (>50 μm) were quantified after 5 days of plating, 
and plotted. Error bars represent ±S.D, * p <0.05, NS- not significant.
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Figure 10: PTC-209 inhibits BCSC markers and inhibition of miR-141 and miR-200c overcome PTC-209 inhibitory 
effect on BCSC markers. A. ALDH1 activity of control, and miR-141 and miR-200c inhibitors expressing MDA-MB-231 cells treated 
with DMSO (mock) or PTC-209 (1.0 μM) (as indicated) was determined using an ALDEFLUOR kit as described in the Experimental 
Methods. DEAB+ sets are controls. B. CD44 expression in control, miR-141 inhibitor and miR-200c inhibitor expressing MDA-MB-231 
cells treated with DMSO (mock) or PTC-209 (1.0 μM) (as indicated) was determined by FACS analysis described in the Methods.
Figure 11: Schematic representation of the miR-200c/141-BMI1 autoregulatory loop and its relevance to cancer and 
ageing. PTC-209 inhibits BMI1 expression. BMI1 transcriptionally downregulates tumor suppressive miRNAs, in particular miR-141 and 
miR-200c. MiR-141 and miR-200c posttranscriptionally downregulate BMI1, which in turn transcriptionally downregulates expression 
of miR-200c/141 cluster completing an autoregulatory loop. A fine-tuned level of BMI1 and miR-200c/141 via this autoregulatory loop 
maintains a normal balance between the proliferation and senescence in an organism necessary for its normal physiology. Upregulation of 
BMI1 due to the inhibition of miR-200c/141 cluster could promote cancer stem cell phenotype and therefore development of cancer, while 
upregulation of miR-200c/141 cluster could inhibit adult- or organ-specific stem cells, which may promote age-related pathologies and 
premature ageing.
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MATERIALS AND METHODS
Cell culture and reagents
MDA-MB-231, MCF7 and 293T (SV40 T 
expressing HEK293) cells were obtained from American 
Type Culture Collection (ATCC) (Manassas, VA). The 
cells were cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM) containing 5% Fetal Bovine Serum 
(FBS) as described [25, 27]. MRC5 strain of human 
diploid fibroblast (HDF) was obtained from the Coriell 
Institute for Medical Research Aging Cell Repository 
(Camden, NJ), and cultured as described (25, 27). 
PTC-209 (N-(2,6-dibromo-4-methoxyphenyl)-4-(2-
methylimidazo[1,2-a]pyrimidin-3-yl)-2-thiazolamine) was 
obtained from the Cayman Chemicals (Ann Arbor, MI), 
dissolved in DMSO (dimethyl sulfoxide), and added to the 
cell culture medium as described [24].
Expression vectors, promoter-reporters, 
transient transfections, retrovirus and lentivirus 
production, and luciferase assays
Lentiviral vector pEZX-MR03 expressing miR-200c 
and miR-141 pre-miRNAs, and pEZX-AM03 expressing 
miR-200c and miR-141 inhibitors (miArrest™ miRNA) 
were obtained from the Genecopoeia (Rockville, MD). 
The pBabe-puro retroviral vector overexpressing wild 
type BMI1, and BMI1 shRNA (in pRetro-super (RS) 
vector) and pcDNA-BMI1 have been described previously 
[25, 27]. For stable clone generation, retroviruses were 
produced, and target cells were infected and selected in 
0.5-1 μg/ml puromycin as described [25, 27, 49]. Cloning 
of the promoter region of the miR-200c/141 cluster has 
been described earlier [28]. Briefly, to generate a wild-
type hsa-miR-200c/141 promoter reporter construct, the 
upstream promoter region (-683 to -44 bp) was PCR-
amplified with a primer set (WT F and R primers, Table 1) 
and cloned into the pGL4.18 vector (Promega, Madison, 
WI). The mutant reporter constructs were generated using 
Quick Change Site-Directed Mutagenesis Kit (Agilent 
Technology) according to the manufacturer’s protocol. 
The primer sets used in the site-directed mutagenesis are 
described in Table 1. The primer sets M1 and M2 were 
used to generate mutant 3 (M3). The reporter constructs 
were transiently transfected into 293T cells using calcium 
phosphate method, and promoter-reporter assays were 
performed using Dual-Luciferase® Reporter Assay 
System as described [25, 27].
Antibodies and western blot analyses
The BMI1 mouse monoclonal antibody (mAb) F6, 
p16INK4a (p16) mAb and β-actin mAb were obtained 
from Invitrogen (Carlsbad, CA), Santa Cruz Biotechnology 
(Santa Cruz, CA) and Sigma-Aldrich (St Louis, MO), 
respectively. The rabbit polyclonal antibodies (pAbs) 
against H3 and H2A, and mAbs against H4, H3 and acetyl 
histone H3 were obtained from Cell Signaling Technology 
(Danvers, MA). The H3K27me3 and H2AK119Ub pAbs 
were obtained from Millipore (Billerica, MA). Western 
blot analyses using antibodies specific to the protein of 
interest were done as described previously [24, 50].
Quantitative RT-PCR (qRT-PCR) and 
chromatin-immunoprecipitation-linked PCR 
(ChIP) analyses
The qRT-PCR assays were performed as described 
[27]. Briefly, total RNA was isolated using TRIzol 
reagent as described by manufacturer (Invitrogen, 
Carlsbad, CA), and treated with DNase (Promega, 
Madison, WI). For miRNA qRT-PCR, miR-141 and 
miR-200c specific primers, and cDNA synthesis kit were 
from Quanta Biosciences (Gaithersburg, MD). The PCR 
conditions consisted of an initial activation at 50°C for 
2 min, 95°C for 20 sec followed by 40 cycles of 95°C 
for 1 sec, and 60°C for 20 sec in the Step One Plus 
Real-Time PCR system (Applied Biosystems). The Ct 
(threshold cycle) value of each primer was normalized 
to that of RNU6B for miRNA or GAPDH for other genes 
as internal controls. The chromatin immunoprecipitation 
(ChIP) assays were performed as described [25, 50]. 
The immunoprecipitated chromatin was amplified using 
different sets of miR-200c/141 promoter specific primers 
(Table 2) by qPCR in a Step-one plus RT-PCR machine 
(ABI).
Proliferation, senescence and mammosphere 
formation assays, and analysis of cancer stem 
cell (CSC) markers
Proliferation and senescence assays were 
performed as described [36, 51]. The EdU (5’ ethynyl 
-2’-deoxyuridine, a thymidine analog) and senescence-
associated beta galactosidase (SA-β-Gal) co-staining 
was performed as described [52]. Images were captured 
with a Nikon Eclipse Ti microscope camera under 
10X magnification and stained cells were counted as 
described [53]. Mammosphere formation and Aldefluor 
assays, and FACS analysis of CD44 marker to determine 
breast cancer stem cell phenotype were done as 
described [25, 26, 28].
Statistical analysis
All experiments were performed multiple times 
with triplicates for each group. Results are presented 
as the mean ± S.D., and the statistical significance was 
determined using Student’s t test. The p < 0.05 was 
considered significant.
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